Why Does Wegovy Cause Nausea? The Biology Behind Semaglutide-Induced GI Side Effects

What the trials recorded

Three placebo-controlled trials, pooled: 2,116 adults on Wegovy 2.4 mg weekly and 1,261 on placebo, treatment up to 68 weeks. Nausea 44% versus 16%; diarrhea 30% versus 16%; vomiting 24% versus 6%; constipation 24% versus 11%; abdominal pain 20% versus 10%; dyspepsia 9% versus 3%; eructation 7% versus <1%. Any gastrointestinal reaction was reported by 73% versus 47% [1].

Discontinuation ran well below those rates. In the same pooled trials, 6.8% of people on Wegovy and 3.2% on placebo stopped treatment for any adverse reaction; nausea was the reason for 1.8% versus 0.2%, vomiting 1.2% versus 0%, diarrhea 0.7% versus 0.1% [1].

Two mechanisms the label names

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. More than 99% is bound to albumin, and its elimination half-life is about a week [1]. The label describes two actions that matter here: it selectively binds and activates the GLP-1 receptor, including receptors in brain areas that regulate appetite and calorie intake, and it delays gastric emptying [1].

The brain side

Wegovy activates GLP-1 receptors in brain areas involved in appetite [1]. The finer mapping comes from rodent work with two other peripherally given GLP-1 receptor agonists, exendin-4 and liraglutide. In rodents, blocking brain GLP-1 receptors reduced a nausea-like response to exendin-4, a different drug [3]. Every peripheral dose of exendin-4 that suppressed food intake also produced conditioned taste avoidance, a nausea-like response, and repeated dosing produced pica, the eating of non-nutritive material. That pica response was not prevented by cutting the vagus nerve, while direct injection into the medial subnucleus of the nucleus tractus solitarius reduced food intake and produced pica [3]. That work did not test semaglutide or people, so it does not show whether the same pathway explains nausea with Wegovy [3].

The stomach side

Wegovy delays gastric emptying; the label gives this as the reason it can change the absorption of oral medicines [1]. One direct measurement comes from a randomised, double-blind, placebo-controlled crossover trial of 30 adults with obesity. Semaglutide was escalated to 1.0 mg weekly over each 12-week treatment period, and emptying was measured by paracetamol absorption after a standard meal. First-hour paracetamol absorption AUC was lower with semaglutide 1 mg than with placebo (ratio 0.73, 95% CI 0.61 to 0.87). The five-hour measure was not statistically different [2].

That measurement was at 1 mg, not the 2.4 mg maintenance dose.

Does a higher dose cause more nausea?

In two 72-week trials, 1,311 adults were in the 7.2 mg treatment arm and 1,149 received at least one 7.2 mg dose after escalation; 304 were in the 2.4 mg arm and 303 on placebo. Nausea was reported by 39% of adults assigned to 7.2 mg, 35% assigned to 2.4 mg and 13% assigned to placebo [1]. Vomiting was 22% / 16% / 6%; constipation 20% / 19% / 8%; treatment stopped for gastrointestinal reasons in 3% / 3% / 0.3% [1]. Both doses sat far above placebo.

Wegovy tablets also caused gastrointestinal reactions: in the label's 64-week tablet trial of 204 adults, severe gastrointestinal reactions occurred in 2% versus 0% on placebo [1]. In the OASIS 4 trial of 307 adults, gastrointestinal adverse events were reported by 74.0% on oral semaglutide 25 mg versus 42.2% on placebo [4].

Why the schedule starts low

Wegovy injection starts at 0.25 mg weekly for 4 weeks, then 0.5 mg (weeks 5 to 8), 1 mg (weeks 9 to 12) and 1.7 mg (weeks 13 to 16), with maintenance from week 17 at 2.4 mg (recommended) or 1.7 mg. Adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss may go to a maximum of 7.2 mg weekly [1]. The escalation table exists to minimize gastrointestinal adverse reactions, and an April 2024 version of the label says that if a dose is not tolerated during escalation, delaying escalation for 4 weeks can be considered [5].

How long does nausea last?

The 44% figure is a single total across trials of up to 68 weeks, not a week-by-week course [1], and we found no published breakdown of nausea rates at each dose step. What the label does show is how often nausea ended treatment: 1.8% on Wegovy 2.4 mg versus 0.2% on placebo across those trials [1]. In STEP 1, the 68-week trial of 1,961 adults, 4.5% on semaglutide and 0.8% on placebo stopped treatment for gastrointestinal events [6].

What the label flags alongside nausea

Persistent severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting, can be a sign of acute pancreatitis, and the label says to discontinue Wegovy if it is suspected [1]. Confirmed acute pancreatitis occurred in 4 Wegovy-treated adults, 0.2 cases per 100 patient-years, versus 1 on placebo [1].

Gallbladder disease is labelled with these rates in adults: cholelithiasis 1.6% versus 0.7% and cholecystitis 0.6% versus 0.2%; in the pediatric trial, cholelithiasis was 3.8% versus 0% [1].

Severe gastrointestinal reactions have their own warning: 4.1% versus 0.9% in the injection trials and 2% versus 0% with the 25 mg tablets. The label says Wegovy is not recommended in patients with severe gastroparesis, and lists postmarketing reports of ileus, intestinal obstruction and severe constipation with fecal impaction; it does not state that semaglutide causes gastroparesis [1].

Acute kidney injury from volume depletion appears at 0.4 versus 0.2 cases per 100 patient-years, more often in people with existing kidney impairment and during titration, and often after gastrointestinal fluid loss [1].